A Pilot Trial to Determine the Efficacy of Lactobacillus Rhamnosus for Reducing Colonization by Methicillin-resistant Staphylococcus Aureus (MRSA) (PROSE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the feasibility, safety and efficacy of oral probiotic, Lactobacillus rhamnosus versus oral placebo for reducing colonization by MRSA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Probiotics Pilot Project

NCT04247854

Staphylococcus Aureus

UNKNOWN NA

Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19

NCT04399252

Microbiome

COMPLETED NA

The Effect of a Probiotic on Upper Respiratory Tract Infections

NCT03636191

Infections, Upper Respiratory Tract

COMPLETED NA

Impact of Probiotics for Reducing Infections in Veterans: The IMPROVE Study

NCT01321606

Anti-biotic Resistance

COMPLETED PHASE2

Effect of Probiotics on Health-related Quality of Life in College Students With Upper Respiratory Infections

NCT01657643

Upper Respiratory Infection

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Healthcare-associated infections are an important threat to patient safety. Currently, between 5 and 10 percent of patients admitted to acute care hospitals acquire one or more infections; healthcare-associated infections affect approximately 2 million patients each year in the United States, result in 90,000 deaths, and are associated with an added cost of $4.5 to $5.7 billion per year. Seventy percent of healthcare-associated infections are caused by antimicrobial resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), resulting in increased antimicrobial usage, morbidity and mortality, making prevention of multiresistant bacteria essential.

Eradication of colonization has been shown to greatly reduce infection; however, there are no reliable means of providing sustained eradication of colonization. No effective means of eradicating MRSA colonization exist.

Probiotics containing strains of lactobacilli represent a novel approach to the prevention and control of antimicrobial resistance and have been studied extensively for a variety of infections. Even though various studies have shown probiotics to be effective for prevention of vaginal infections, urinary tract infections, etc no studies have examined the potential of probiotics to eradicate colonization by resistant pathogens, such as MRSA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic

subjects will be given a pill formulation of a probiotic Lactobacillus rhamnosus to be taken once a day.

Group Type EXPERIMENTAL

Lactobacillus rhamnosus

Intervention Type DIETARY_SUPPLEMENT

1 pill formulation to be given once a day for 4 weeks

Sugar pill

placebo identical to the active product will be given

Group Type PLACEBO_COMPARATOR

Sugar pill (placebo)

Intervention Type DIETARY_SUPPLEMENT

placebo identical to the active product will be given

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lactobacillus rhamnosus

1 pill formulation to be given once a day for 4 weeks

Intervention Type DIETARY_SUPPLEMENT

Sugar pill (placebo)

placebo identical to the active product will be given

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Yoplait Activia splenda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* subjects will be male or female
* 18 years of age or older
* may or may not be hospitalized
* able to take oral medications
* have been found to be colonized with MRSA or at high risk of being colonized by MRSA and are not taking antibiotics